$11.110
-0.358 (-3.22%)收盘时
PHAR 资讯
PHAR 事件
RUCONEST Q2 Revenue at $90.2M, Below Consensus
Reports Q2 revenue $90.2M, consensus $99.52M. CEO, Fabrice Chouraqui, commented: "While we have lowered our full-year revenue guidance, we are encouraged by the resilience of RUCONEST, a year after the launch of the first oral on-demand HAE treatment. The active patient base remained at 93% of year ago levels, and RUCONEST continues to be a cornerstone on-demand treatment for high-burden HAE patients. Supported by strong new patient enrollments in the second quarter, we expect RUCONEST revenues to stabilize and return to growth during the second half of 2026."
Cuts FY26 Operating Expenses Outlook to $315M-$320M
Consensus $404.01M. Cuts FY26 operating expenses view to $315M-$320M from $330M-$335M.
Pharming Group Receives EU Marketing Authorization for Joenja
Pharming Group announced that the European Commission has granted marketing authorization for Joenja, an oral, selective phosphoinositide 3-kinase delta inhibitor, for the treatment of activated PI3K delta syndrome, a rare primary immunodeficiency, in adult and pediatric patients 12 years of age and older. Joenja is the first and only approved treatment for APDS in the European Union. The first European launch is expected in Germany in Q3 2026, with additional launches anticipated pending completion of national reimbursement negotiations.
Pharming Sees FY26 Operating Expenses at $330M-$335M
Sees FY26 operating expenses $330M-$335M. The company said, "Finally, our focus on financial discipline also delivered tangible results, including positive net cash flow from operations in the quarter despite quarterly revenue variability. Taken together, our commercial execution, regulatory progress, pipeline advancement, and disciplined financial management position Pharming well for sustained long-term growth and value creation."
Company Reports Q1 Revenue of $72.45M, Below Consensus
Reports Q1 revenue $72.45M, consensus $92.07M. The company said, "The first quarter demonstrated important progress across the business while also reflecting revenue variability for RUCONEST. Joenja delivered strong revenue growth of 34% year over year, driven by robust patient uptake, reinforcing its role as an important growth driver still early in its lifecycle. We also made meaningful regulatory progress, including approval in Japan for APDS patients aged 4 and older and a positive CHMP opinion in Europe. In the U.S., constructive dialogue with the FDA following receipt of the CRL enabled us to already resubmit our pediatric sNDA for the two highest doses, which cover a meaningful proportion of children aged 4 to 11, and plan an additional sNDA submission for the lowest doses this summer."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。